Abbott, AstraZeneca seek cholesterol pill approval

Jun 04, 2009

(AP) -- Abbott Laboratories and AstraZeneca PLC on Thursday asked the Food and Drug Administration to approve a drug that combines their cholesterol pills TriLipix and Crestor.

Abbott's TriLipix is part of a class of drugs called fibrates that raise "good" HDL while reducing triglycerides and "bad" . AstraZeneca's Crestor is a statin drug that lowers bad cholesterol while raising good cholesterol.

Studies conducted by the companies compared the combination pill versus separate treatment with statin and fibrate drugs.

The companies' application to the FDA seeks approval to treat dyslipidemia, a disorder characterized by elevated cholesterol and , a type of fat found in the . More than 100 million adults in the U.S. have the disorder, according to the American Heart Association.

If approved, the drug would be marketed under the brand name Certriad.

Crestor was London-based AstraZeneca's third best-selling product last year with sales of $3.6 billion. Trilipix was launched last December. The drug had sales of $253 million in the first quarter, when combined with a related treatment called Tricor.

The two companies also said Thursday that AstraZeneca will begin co-promoting Trilipix to physicians in the U.S. Financial terms of the agreement were not disclosed.

U.S. shares of slipped 7 cents to $40.77 in late morning trading while Abbott shares fell 57 cents to $44.55.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: Rapivab approved to help treat flu

add to favorites email to friend print save as pdf

Related Stories

Study: Cholesterol drug lowers blood clot risk

Mar 29, 2009

(AP) -- Statin drugs, taken by millions of Americans to lower cholesterol and prevent heart disease, also can cut the risk of developing dangerous blood clots that can lodge in the legs or lungs, a major study suggests.

AstraZeneca, Merck collaborate on cancer treatment

Jun 01, 2009

(AP) -- AstraZeneca PLC and Merck & Co. said Monday they will jointly develop a pair of drugs meant to hit cancer with a one-two punch, part of a growing trend of combination cancer treatments.

High triglycerides, other cholesterol raise risk of stroke

Dec 27, 2007

People with high triglycerides and another type of cholesterol tested but not usually evaluated as part of a person’s risk assessment have an increased risk of a certain type of stroke, according to research published in ...

Trials find no benefits of Zetia

Jan 15, 2008

The U.S. makers of the cholesterol-lowering drug Zetia say a clinical trial failed to identify any medical benefits of the medication.

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

15 hours ago

The nation's largest pharmacy benefits manager is throwing its weight into the fight over high-cost hepatitis C drugs with a coverage restriction that might ultimately lower prices and improve patient access ...

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.